Areteia Therapeutics is focused on developing dexpramipexole, a first-in-class oral medication aimed at treating eosinophilic asthma, a severe and often difficult-to-manage form of asthma affecting millions globally. Dexpramipexole works by inhibiting the maturation of eosinophils, which are white blood cells that contribute to inflammation and damage in the airways. The drug has shown promise in multiple clinical trials, demonstrating significant reductions in eosinophil counts in both blood and inflamed tissue, as well as improvements in lung function. With over 1,500 patients assessed across various indications, dexpramipexole is positioned as a potential breakthrough in the treatment landscape for eosinophilic asthma.

Currently, Areteia is advancing dexpramipexole through Phase III clinical trials, which are critical for securing regulatory approvals and paving the way for global commercialization. These trials aim to evaluate the efficacy of dexpramipexole in reducing asthma exacerbations and improving lung function in patients inadequately controlled by existing therapies. The company’s commitment to addressing the unmet needs of eosinophilic asthma patients is underscored by its extensive research and development efforts, which leverage a deep understanding of the disease and the biological mechanisms involved in eosinophil maturation and inflammation.

United States

Areteia Therapeutics is a clinical stage biotechnology company committed to putting respiratory patients in better control of their disease—and back in control of their lives. The company's purpose is to develop and deliver novel inflammation modulating therapies to improve the lives of patients with respiratory diseases. Areteia Therapeutics is dedicated to advancing the treatment of respiratory diseases, including asthma and eosinophilic asthma, through innovative research and development.

Areteia Therapeutics

Company Details